Sharon Pitteri
Academic Appointments
- Assistant Professor (Research), Radiology - Diagnostic Radiology
- Member, Stanford Cancer Institute
- Member, Bio-X
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 723-6076
Professional Overview
Professional Education
| Post Doctoral: | Fred Hutchinson Cancer Research Center (2010) |
| PhD: | Purdue University, Chemistry (2005) |
| BA: | Carleton College, Chemistry (2001) |
Internet Links
Scientific Focus
Current Research Interests
The Pitteri laboratory is focused on the discovery and validation of proteins that can be used as molecular indicators of risk, diagnosis, progression, and recurrence of cancer. Proteomic technologies, predominantly mass spectrometry, are used to identify proteins in the blood that are differentially regulated and/or post-translationally modified with disease state. Using human plasma samples, tumor tissue, cancer cell lines, and genetically engineered mouse models, the origins of these proteins are being investigated. A major goal of this research is to define novel molecular signatures for breast and ovarian cancers, including particular sub-types of these diseases. This laboratory is also focused on the identification of proteins with expression restricted to the surface of cancer cells which can be used as novel targets for molecular imaging technologies.
Publications
- Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res. 2013; (5): 1502-13
- Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. Cancer Res. 2012; (8): 1935-42
- Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila). 2012; (8): 1036-43
- Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila). 2012; (4): 655-64
- Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer. 2012; (4): 546-52
- Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012; (5): 1071-81
Help